Ixazomib

Ixazomib is a glycine derivative that is the amide obtained by formal condensation of the carboxy group of N-(2,5-dichlorobenzoyl)glycine with the amino group of [(1R)-1-amino-3-methylbutyl]boronic acid. The active metabolite of ixazomib citrate, it is used in combination therapy for treatment of multiple myeloma. Among its listed roles, it functions as a apoptosis inducer, an orphan drug, a proteasome inhibitor, a drug metabolite and an antineoplastic agent. It belongs to the class of benzamides, a dichlorobenzene, a glycine derivative and a member of boronic acids. It is grouped under the following drug class(es): Proteasome inhibitors. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include CHEBI:90942, DTXSID701025662 and MFCD18251438. Its PubChem CID is 25183872.

CAS No 1072833-77-2
Molecular Formula C14H19BCl2N2O4
Molecular Weight 361.0 g/mol
Synonyms [(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]boronic acid

Frequently Asked Questions